

UCREST BERHAD

(Company No.: 420056-K)

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 AUGUST 2024**

	Current Quarter Ended 31-Aug-2024 RM'000	Comparative Quarter Ended 31-Aug-2023 RM'000	Cumulative Year To Date 31-Aug-2024 RM'000	Cumulative Year To Date 31-Aug-2023 RM'000
Income				
Revenue	2,646	1,992	2,646	1,992
Cost of sales	(2,139)	(1,245)	(2,139)	(1,245)
Gross Profit	<u>507</u>	<u>747</u>	<u>507</u>	<u>747</u>
Other income	1,823	1,872	1,823	1,872
Total Income	4,469	3,864	4,469	3,864
Expenses				
Selling and distribution	(27)	(12)	(27)	(12)
Administrative and general expenses	(1,144)	(962)	(1,144)	(962)
Profit / (Loss) from Operations (EBITA)	<u>1,159</u>	<u>1,645</u>	<u>1,159</u>	<u>1,645</u>
Amortisation of Intangible Assets	(657)	(657)	(657)	(657)
Depreciation	(43)	(44)	(43)	(44)
Profit / (Loss) Before Interest and Taxes (EBIT)	<u>459</u>	<u>944</u>	<u>459</u>	<u>944</u>
Finance Cost	(2)	(4)	(2)	(4)
Profit / (Loss) before Tax	<u>457</u>	<u>940</u>	<u>457</u>	<u>940</u>
Profit / (Loss) before tax is stated after charging/(crediting):-				
Interest income	(105)	(74)	(105)	(74)
Reversal of impairment loss on trade receivables	(1,695)	(1,729)	(1,695)	(1,729)
Depreciation and amortisation	701	701	701	701
Foreign exchange (gain) / loss	217	(48)	217	(48)
Income tax expense	-	-	-	-
Profit / (Loss) for the period	<u>457</u>	<u>940</u>	<u>457</u>	<u>940</u>
Foreign currency translation	(2,525)	106	(2,525)	106
Total Comprehensive Profit / (Loss)	<u>(2,068)</u>	<u>1,046</u>	<u>(2,068)</u>	<u>1,046</u>
Attributable to :-				
Owners of the Company	457	940	457	940
Non-Controlling Interests	-	-	-	-
	<u>457</u>	<u>940</u>	<u>457</u>	<u>940</u>
Total comprehensive profit / (loss) attributable to:-				
Owners of the Company	(2,068)	1,046	(2,068)	1,046
Non-Controlling Interests	-	-	-	-
	<u>(2,068)</u>	<u>1,046</u>	<u>(2,068)</u>	<u>1,046</u>
Earnings / (Loss) per share - Basic (sen)	0.06	0.13	0.06	0.13
- Diluted (sen)	0.06	0.13	0.06	0.14

Note:

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the audited financial statements for the period ended 31 May 2024 and the accompanying explanatory notes attached to the interim financial statements.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 AUGUST 2024

	As At 31 Aug 2024 RM'000	As At 31 May 2024 RM'000
<u>ASSETS</u>		
Non-Current Assets		
Property, Plant and Equipment	34	38
Right-of-use Assets	125	164
Intangible Assets	1,682	2,339
Trade Receivables	18,099	19,739
Total Non-Current Assets	<u>19,940</u>	<u>22,280</u>
Current Assets		
Trade Receivables	10,736	11,095
Other Receivables	100	102
Tax Recoverable	356	335
Deposits, Cash and Bank Balances	17,389	19,137
Total Current Assets	<u>28,581</u>	<u>30,669</u>
Total Assets	<u>48,521</u>	<u>52,949</u>
<u>EQUITY AND LIABILITIES</u>		
Capital and Reserves		
Share Capital	56,971	56,754
Reserves	(16,406)	(14,314)
Total Equity	<u>40,565</u>	<u>42,440</u>
Current Liabilities		
Trade Payables	7,547	10,042
Other Payables	268	286
Leased Liabilities	141	181
Bank Overdraft	-	-
Total Current Liabilities	<u>7,956</u>	<u>10,509</u>
Total Liabilities	<u>7,956</u>	<u>10,509</u>
Total Equity and Liabilities	<u>48,521</u>	<u>52,949</u>
Net Assets Per Share Attributable to owners of the Company (Sen)	5	6

Note:

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the year ended 31 May 2024 and the accompanying explanatory notes attached to the interim financial statements.

UCREST BERHAD

(Company No.: 420056-K)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 AUGUST 2024**

	Share Capital RM'000	Foreign Currency translation Reserve RM'000	ESOS Reserve RM'000	Accumulated Loss RM'000	Equity Attributable to the Owners of the Company RM'000	Total Equity RM'000
<u>Quarter ended 31 Aug 2024</u>						
Balance as at 1 Jun 2024 (Audited), As previously stated	56,754	2,050	461	(16,825)	42,440	42,440
Issuance of shares pursuant to private placement	-	-	-	-	-	-
Share options granted under ESOS	217	-	(24)	-	193	193
Lapsed share options	-	-	-	-	-	-
Profit/(loss) for the period	-	(2,525)	-	457	(2,068)	(2,068)
Comprehensive profit/(loss) for the period	217	(2,525)	(24)	457	(1,875)	(1,875)
Balance as at 31 Aug 2024 (Unaudited)	56,971	(475)	437	(16,368)	40,565	40,565

Note:

The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 May 2024 and the accompanying notes attached to the interim financial statements.

**CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 31 AUGUST 2024**

	3 Months to date ended 31/08/2024 RM'000	12 Months to date ended 31/05/2024 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	457	4,592
Adjustments for:		
Amortisation of intangible assets	657	2,628
Depreciation of property, plant and equipment	4	17
Depreciation of right-of-use asset	39	157
Impairment loss on trade receivables	-	1
Reversal of impairment loss on receivables	(1,695)	(7,065)
ESOS expenses	-	334
Finance costs	2	14
Interest income	(105)	(476)
Unrealised gain on foreign exchange translation	489	(198)
Unrealised loss on foreign exchange translation	(284)	160
Operating (loss)/profit before changes in working capital	<u>(436)</u>	<u>164</u>
Changes in working capital:-		
Trade and other receivables	3,652	(582)
Trade and other payables	<u>(2,228)</u>	<u>(4,153)</u>
Cash used in operations	988	(4,571)
Interest received	105	476
Tax refund	-	476
Tax paid	<u>(21)</u>	<u>(92)</u>
Net cash generated from / (used in) operating activities	<u>1,072</u>	<u>(3,711)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment	-	(16)
Net cash used in investing activities	<u>-</u>	<u>(16)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceed from issuance of share capital		
- private placement	-	4,675
- pursuant to exercise of ESOS	193	-
Repayment of lease liability	(40)	(152)
Interest paid	<u>(2)</u>	<u>(14)</u>
Net cash generated from financing activities	<u>151</u>	<u>4,509</u>
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	1,223	782
CASH AND CASH EQUIVALENTS AT 01 JUNE	19,137	17,633
EFFECTS OF EXCHANGE RATE CHANGES	(2,971)	722
CASH AND CASH EQUIVALENTS AS AT END OF THE FINANCIAL PERIOD	<u>17,389</u>	<u>19,137</u>

Cash and cash equivalents

Cash and cash equivalents included in the statements of cash flows comprise the following statements of financial position amounts:

Deposits	11,887	13,331
Cash and bank balances	5,502	5,806
	<u>17,389</u>	<u>19,137</u>

Note:

The condensed consolidated cash flow statement should be read in conjunction with the audited financial statements for the year ended 31 May 2024 and the accompanying notes attached to the interim financial statements.

SELECTED EXPLANATORY NOTES

1. Accounting Policies and Methods Of Computation

The current quarter financial report ended 31 Aug 2024 is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market.

The report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 May 2024. The explanatory notes attached to the quarterly financial report provide an explanation on events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 May 2024.

The accounting policies and methods of computation adopted by the Group in the quarterly financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 May 2024.

2. Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the audited financial statements for the year ended 31 May 2024 was not qualified.

3. Segmental Reporting

Geographical information

	<u>Individual Quarter Ended</u>		<u>Individual YTD</u>	
	<u>31-Aug-24</u>	<u>31-Aug-23</u>	<u>31-Aug-24</u>	<u>31-Aug-23</u>
	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>	<u>RM'000</u>
Malaysia	58	60	58	60
International	2,588	1,932	2,588	1,932
Group revenue	<u>2,646</u>	<u>1,992</u>	<u>2,646</u>	<u>1,992</u>

4. Unusual Items

During the quarter under review, there were no unusual items affecting assets, liabilities, equity, net income, or cash flows of the Group.

5. Changes In Estimates Of Amount Reported Previously Affecting Current Interim Period

There are no changes in estimates of amount reported that will have a material effect in the current interim period.

6. Seasonality or Cyclicity

The operations of the Group are not subject to any seasonality or cyclicity factors.

7. Dividends Paid Or Proposed

Dividends were neither paid nor proposed during the current interim period.

8. Valuation of Property, Plant and Equipment

The Group has not carried out any valuation on its property, plant & equipment.

9. Debts and Equity Securities

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities.

10. Change In The Composition of The Group

There has been no change in the composition of the group for the quarter review.

SELECTED EXPLANATORY NOTES

11. Discontinued Operation

There were no discontinued operations within the activities of the Group for the quarter under review.

12. Capital Commitments

There were no capital commitments for the purchase of any property, plant and equipment or any other expenses that were not accounted for in the financial statements of the quarter under review.

13. Changes In Contingent Liabilities & Assets

There are no material contingent liabilities as at the date of this report.

14. Subsequent Events

There were no material events subsequent to the end of the reporting quarter that have not been reflected in the quarter under review.

Additional Information As Per ACE Market Listing Requirement

15. Review Of Performance

During the current quarter under review, the Group recorded a net profit attributable to Owners of the Company of RM0.457 million.

16. Material Change In the Profit / (Loss) Before Taxation Compared To The Results of :-

	<u>Immediate Preceding Quarter</u>		<u>Individual Quarter Ended</u>		<u>Culmuative YTD</u>	
	<u>31-Aug-24</u>	<u>31-May-24</u>	<u>31-Aug-24</u>	<u>31-Aug-23</u>	<u>31-Aug-24</u>	<u>31-Aug-23</u>
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
P/(L)BITDA	1,159	1,519	1,159	1,645	1,159	1,645
Less : Amortisation of intangible assets	(657)	(657)	(657)	(657)	(657)	(657)
Less : Depreciation	(43)	(44)	(43)	(44)	(43)	(44)
Less : Impairment loss on trade receivables	-	(1)	-	-	-	-
Less : Finance cost	(2)	(3)	(2)	(4)	(2)	(4)
Profit / (Loss) before tax	457	814	457	940	457	940

The Group recorded profit before tax of RM 0.457 million in the current quarter, and profit before tax of RM 0.814 million in the immediate preceding quarter.

17. Commentary Of Prospects

Q1 FY2025 overall revenue increased by 16% from the same quarter in FY2024, its core revenue increased by 32%, marking a steady growth of revenue over FY2024. The early adopters of the customers are embracing quickly in a significant way whilst the mainstream and conservative users are still looking on at the side line. The Group has inked a deal of approximately RM5 million over the next 3 years to digitalize and automate Singapore Paincare Holdings consisting of 5 specialist paincare centers, 10 GP clinics, 2 physiotherapy and 1 TCM center. We expect more of the similar deals with come through and our strategic focus is on clinics that are bigger chain and innovative. Substantial investment is made over past 2 quarters in developing the capabilities and features needed for the Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) business in the US. The team has been working extra hard and V1.0 is expected to release in next 60 days. We expect the business to increase substantially once iMedic America version is in the hands of the practices in the US market.

The Group is investing more into AI of specific diseases and we expect to roll out more AI products that are far more superior than the competitors.

18. Profit Forecast

There was no profit forecast issued by the Group.

SELECTED EXPLANATORY NOTES

19. Taxation

There were no tax provision during the current interim period under review.

20. Unquoted Investments / Properties

There were no purchase or sales of unquoted investments or properties during the current interim period under review.

21. Purchase or Disposal of Quoted Securities

There were no purchase or disposal of quoted securities during the current interim period under review.

22. Status of Corporate Proposal

The Company had at the Annual General Meeting held on 25 November 2022 obtained the shareholders' approval for a private placement exercise to issue up to 70,481,900 new ordinary shares in the Company representing not more than ten percent (10%) of the issued share capital of the company ("Private Placement").

Bursa Securities had, vide its letter dated 25 May 2023, approved the listing and quotation of up to 70,481,900 Placement Shares to be issued pursuant to the Private Placement.

As at the date of this report, 50,000,000 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the ACE Market of Bursa Malaysia Securities Berhad.

Bursa Malaysia Securities Berhad had, vide its letter dated 20 November 2023, granted the Company approval for an extension of time of six months from 25 November 2023 to 24 May 2024 to complete the Proposed Private Placement.

Subsequently, Bursa Malaysia Securities Berhad had, vide its letter dated 28 May 2024, granted the Company approval for an extension of time of six months from 25 May 2024 to 24 November 2024 to complete the Proposed Private Placement.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Working capital	6,213	4,570	1,643
Expenses for the proposed private placement	130	105	25

23. Group Borrowings and Debt Securities

There were no borrowings and debts securities for the financial quarter under review.

24. Off Balance Sheet Financial Instruments

There were no off balance sheet financial instruments as at the date of this report.

25. Material Litigation

There were no Material Litigation for the financial quarter under review.

SELECTED EXPLANATORY NOTES

26. Realised and Unrealised Profits/Losses

On 25 March 2010, Bursa Securities issued a directive to all listed issuers pursuant to Rules 2.07 and 2.23 of Bursa Securities ACE Market Listing Requirements. The directive requires all listed issuers to disclose the breakdown of the unappropriated profits or accumulated losses as at the end of the reporting period, into realised and unrealised profits and losses.

On 20 December 2010, Bursa Securities further issued guidance on the disclose and the format period.

The breakdown of accumulated profit / (losses) of the Group as at the reporting date, into realised and unrealised losses, pursuant to the directive, is as follows:

	Group	
	<u>Unaudited</u> 31/08/2024 RM'000	<u>Audited</u> 31/05/2024 RM'000
Total accumulated profit / (losses) of UCrest Berhad and it's subsidiaries:		
- Realised	(16,208)	(16,660)
- Unrealised - in respect of other items of income and expense	(160)	(165)
Total Group accumulated profit as per consolidated accounts	<u>(16,368)</u>	<u>(16,825)</u>

The determination of realised and unrealised losses is based on the Guidance of Special Matter No.1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements, issued by the Malaysian Institute of Accountants on 20 December 2010.

The disclosure of realised and unrealised losses above is solely for complying with the disclosure requirements stipulated in the directive of Bursa Malaysia and should not be applied for any other purposes.

27. Dividends Payable

The Board of Directors does not recommend any interim dividends for the current quarter ended 31 Aug 2024.

28. Earnings / (Loss) Per Share

(a) Basic

The basic earnings / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<u>Individual quarter ended</u>		<u>Cumulative YTD</u>	
	31-Aug-24	31-Aug-23	31-Aug-24	31-Aug-23
Net profit / (loss) attributable to owners of the company (RM'000)	457	940	457	940
Weighted average number of ordinary shares in issue ('000)	741,877	741,877	741,877	741,877
Basic earnings / (loss) per share (sen)	<u>0.06</u>	<u>0.13</u>	<u>0.06</u>	<u>0.13</u>

(b) Diluted

The diluted earning / (loss) per share for the quarter and cumulative year to date are computed as follow:

	<u>Individual quarter ended</u>		<u>Cumulative YTD</u>	
	31-Aug-24	31-Aug-23	31-Aug-24	31-Aug-23
Net profit / (loss) attributable to owners of the company (RM'000)	457	940	457	940
Dilutive shares on option outstanding ('000)	746,665	742,733	746,665	692,102
Diluted earnings / (loss) per share (sen)	<u>0.06</u>	<u>0.13</u>	<u>0.06</u>	<u>0.14</u>